LINK?PING, Sweden--(BUSINESS WIRE)--A focused review titled “Muscle Mass and Glucagon-like Peptide-1 Receptor Agonists: Adaptive or Maladaptive Response to Weight Loss?” was recently published in the renowned cardiovascular scientific journal, Circulation. Authored by AMRA Medical’s Dr. Jennifer Linge, professor Andreas Birkenfeld of University Hospital Tübingen, and associate professor Ian Neeland of University Hospitals Cleveland, the article discusses several aspects of the response associated with weight loss with respect to muscle health..

瑞典林克平——（商業(yè)新聞短訊）——一篇題為“肌肉質(zhì)量和胰高血糖素樣肽-1受體激動(dòng)劑：對(duì)減肥的適應(yīng)性或不適應(yīng)性反應(yīng)”的重點(diǎn)評(píng)論最近發(fā)表在著名的心血管科學(xué)雜志《循環(huán)》上。這篇文章由AMRA Medical的Jennifer Linge博士、蒂賓根大學(xué)醫(yī)院的Andreas Birkenfeld教授和克利夫蘭大學(xué)醫(yī)院的Ian Neeland副教授撰寫(xiě)，討論了與肌肉健康相關(guān)的減肥反應(yīng)的幾個(gè)方面。。

As pharmaceutical treatments, such as GLP-1 agonists, are reaching weight reductions of magnitudes close to those achieved through bariatric surgery, the concerns regarding a possible adverse impact on muscle health are growing. In light of this, the experts aimed to address whether muscle-related changes associated with weight loss treatments such as GLP-1 receptor agonists may be maladaptive (i.e., adversely impacting muscle health/function), adaptive (i.e., a physiologic response to weight loss maintaining or minimally affecting muscle health/function), or perhaps an enhanced response to weight loss (i.e., improved muscle health/function following treatment)..

隨著藥物治療（如GLP-1激動(dòng)劑）的體重減輕程度接近減肥手術(shù)所達(dá)到的程度，人們?cè)絹?lái)越擔(dān)心可能對(duì)肌肉健康產(chǎn)生不利影響。有鑒于此，專家們旨在解決與減肥治療相關(guān)的肌肉相關(guān)變化（如GLP-1受體激動(dòng)劑）是否可能是適應(yīng)不良（即對(duì)肌肉健康/功能產(chǎn)生不利影響），適應(yīng)性（即對(duì)減肥的生理反應(yīng)維持或?qū)∪饨】?功能的影響最?。蛘呖赡苁菍?duì)減肥的增強(qiáng)反應(yīng)（即治療后肌肉健康/功能的改善）。。

Historical studies of GLP-1-based therapies and body composition have reported absolute and/or relative changes in total body lean mass. Results vary greatly from study to study, likely due to, e.g., variations in population characteristics, study durations, and dosing, but also because of the individual heterogeneity in lean mass composition - comprising not only muscle mass, but also organs, bone, fluids, and water in fat tissue..

基于GLP-1的療法和身體成分的歷史研究報(bào)告了全身瘦體重的絕對(duì)和/或相對(duì)變化。不同研究的結(jié)果差異很大，可能是由于人群特征，研究持續(xù)時(shí)間和劑量的變化，也可能是由于瘦體重組成的個(gè)體異質(zhì)性-不僅包括肌肉質(zhì)量，還包括脂肪組織中的器官，骨骼，液體和水。。

The heterogeneity in past study results makes it difficult for clinicians and researchers to determine what is “normal” or “healthy” weight reduction. However, recent studies in this area have utilized gold-standard MRI-based technology and muscle composition assessments including muscle volume (both in liters and as a sex-, height-, weight-, and BMI invariant z-score describing ‘relative or adequate muscle mass’) as well as muscle fat infiltration, providing muscle-specific data on the effect of incretin-based treatments.

。然而，最近在這一領(lǐng)域的研究利用了金標(biāo)準(zhǔn)的基于MRI的技術(shù)和肌肉組成評(píng)估，包括肌肉體積（以升為單位，以及描述“相對(duì)或足夠肌肉質(zhì)量”的性別，身高，體重和BMI不變z評(píng)分）以及肌肉脂肪浸潤(rùn)，提供了關(guān)于腸降血糖素治療效果的肌肉特異性數(shù)據(jù)。

The authors conclude that the introduction of objective and comprehensive ways of assessing muscle health (including accurate and meaningful assessments of muscle quantity, composition, function, mobility, and strength) is important for the future development of GLP-1-based therapies and patient-centric treatment optimization..

作者得出結(jié)論，引入客觀和全面的評(píng)估肌肉健康的方法（包括對(duì)肌肉數(shù)量，組成，功能，活動(dòng)性和力量的準(zhǔn)確和有意義的評(píng)估）對(duì)于基于GLP-1的療法的未來(lái)發(fā)展和以患者為中心的治療優(yōu)化是重要的。。

As drug development activity increases in the obesity indication and branches out towards aiming for weight reduction with preserved muscle health, it is paramount to include measures such as the muscle volume z-score and muscle fat infiltration, in order to understand the safety and benefit of drugs achieving significant and/or rapid weight reduction.

隨著藥物開(kāi)發(fā)活動(dòng)在肥胖適應(yīng)癥中的增加，并轉(zhuǎn)向以保持肌肉健康為目標(biāo)的減肥，至關(guān)重要的是要包括肌肉體積z評(píng)分和肌肉脂肪浸潤(rùn)等措施，以了解藥物的安全性和益處實(shí)現(xiàn)顯著和/或快速減肥。

AMRA is committed to pioneering not only the development of powerful biomarker methodologies such as the muscle volume z-score in order to augment drug development, but also to the generation of normative data, providing context to future clinical trials and basis for interpretation of clinical benefits related to improving/maintaining muscle health.

AMRA不僅致力于開(kāi)發(fā)強(qiáng)大的生物標(biāo)志物方法，如肌肉體積z評(píng)分，以增加藥物開(kāi)發(fā)，而且致力于生成規(guī)范數(shù)據(jù)，為未來(lái)的臨床試驗(yàn)提供背景，并為解釋與改善/維持肌肉健康有關(guān)的臨床益處奠定基礎(chǔ)。

These initiatives will help ensure that the obesity field develops products with safety and the impact on vulnerable populations in mind..

這些舉措將有助于確保肥胖領(lǐng)域開(kāi)發(fā)安全的產(chǎn)品，并考慮到對(duì)弱勢(shì)人群的影響。。

You can read the full article to learn more about MRI-based muscle assessment and its use in determining the relationship between drug-induced weight reduction and muscle health here.

您可以閱讀整篇文章，以了解更多有關(guān)基于MRI的肌肉評(píng)估及其在確定藥物減肥與肌肉健康之間關(guān)系中的用途。

Learn more about AMRA Medical and how the use of MRI-based fat distribution and muscle composition analysis is advancing disease research in metabolic diseases including obesity, and beyond.

了解有關(guān)AMRA Medical的更多信息，以及如何使用基于MRI的脂肪分布和肌肉成分分析來(lái)推進(jìn)包括肥胖在內(nèi)的代謝性疾病的疾病研究。

About AMRA Medical

關(guān)于AMRA Medical

AMRA Medical is a health informatics and precision medicine company that is pioneering body composition analysis, providing cutting-edge solutions to advance both clinical research and patient care initiatives. AMRA's gold-standard technology delivers multiple fat and muscle biomarkers - derived simply from rapid whole-body MRI scans.

AMRA Medical是一家健康信息學(xué)和精準(zhǔn)醫(yī)學(xué)公司，開(kāi)創(chuàng)了人體成分分析的先河，為推進(jìn)臨床研究和患者護(hù)理計(jì)劃提供了前沿解決方案。AMRA的金標(biāo)準(zhǔn)技術(shù)提供多種脂肪和肌肉生物標(biāo)志物，這些標(biāo)志物僅來(lái)自快速的全身MRI掃描。

AMRA is committed to driving transformative care and simplifying vital decision-making in both research and clinical care settings by offering support services via their innovative platform..

AMRA致力于通過(guò)其創(chuàng)新平臺(tái)提供支持服務(wù)，推動(dòng)變革性護(hù)理，簡(jiǎn)化研究和臨床護(hù)理環(huán)境中的重要決策。。

Learn more about AMRA Medical’s MRI-based solutions at https://amramedical.com/solutions, or connect with our team of experts for a detailed discussion at info@amramedical.com.

了解有關(guān)AMRA Medical基于MRI的解決方案的更多信息，請(qǐng)?jiān)L問(wèn)https://amramedical.com/solutions，或與我們的專家團(tuán)隊(duì)聯(lián)系，在info@amramedical.com.

Follow AMRA on LinkedIn for the latest updates in body composition and precision medicine.

關(guān)注LinkedIn上的AMRA，了解身體成分和精準(zhǔn)醫(yī)學(xué)的最新更新。

相關(guān)知識(shí)

我漂亮的瘦子6：探討瘦身背后的心理健康、飲食科學(xué)與現(xiàn)代審美觀變化
適于健康照明研究的光與情緒實(shí)驗(yàn)方法探討
你真是瘦了：體型變化背后的健康與心理探討
環(huán)境與健康雜志
惡性循環(huán)的警示：肥胖與焦慮的共生
肥胖與心理健康：肥胖與抑郁、焦慮之間是什么樣的關(guān)系？
康復(fù)醫(yī)學(xué)與治療醫(yī)學(xué)關(guān)系的探討
孫超主任/王曉雨醫(yī)師團(tuán)隊(duì)發(fā)現(xiàn)：肝硬化失代償期患者肌肉脂肪變性與各種體成分異常的關(guān)系
自然與健康的關(guān)系：自然療法、探索身心平衡
心理健康與減肥的關(guān)系

網(wǎng)址: 適應(yīng)變化：循環(huán)雜志的新焦點(diǎn)綜述探討了減肥與肌肉健康之間的關(guān)系 http://m.u1s5d6.cn/newsview219815.html